136 related articles for article (PubMed ID: 28662141)
1. SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma.
Pópulo H; Batista R; Sampaio C; Pardal J; Lopes JM; Soares P
PLoS One; 2017; 12(6):e0180392. PubMed ID: 28662141
[TBL] [Abstract][Full Text] [Related]
2. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
3.
Zhang T; Xu M; Makowski MM; Lee C; Kovacs M; Fang J; Willems E; Trent JM; Hayward NK; Vermeulen M; Brown KM
Cancer Res; 2017 Apr; 77(7):1649-1661. PubMed ID: 28108517
[No Abstract] [Full Text] [Related]
4. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma.
Hugdahl E; Kalvenes MB; Mannelqvist M; Ladstein RG; Akslen LA
Br J Cancer; 2018 Jan; 118(1):98-105. PubMed ID: 29123258
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
6. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
7. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
8. BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.
Yilmaz I; Gamsizkan M; Kucukodaci Z; Berber U; Demirel D; Haholu A; Narli G
Indian J Pathol Microbiol; 2015; 58(3):279-84. PubMed ID: 26275246
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein D expression in cutaneous malignant melanoma.
Miranda E; Vizoso F; Martín A; Quintela I; Corte MD; Seguí ME; Ordiz I; Merino AM
J Surg Oncol; 2003 Jun; 83(2):99-105. PubMed ID: 12772203
[TBL] [Abstract][Full Text] [Related]
10. Association of galectin-3 expression with melanoma progression and prognosis.
Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
12. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.
Tas F; Keskin S; Karadeniz A; Dağoğlu N; Sen F; Kilic L; Yildiz I
Oncology; 2011; 81(5-6):353-8. PubMed ID: 22248874
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
14. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
15. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
16. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
17. p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis.
Lee CS; Pirdas A; Lee MW
Australas J Dermatol; 1995 Nov; 36(4):192-5. PubMed ID: 8593106
[TBL] [Abstract][Full Text] [Related]
18. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Heidenreich B; Nagore E; Rachakonda PS; Garcia-Casado Z; Requena C; Traves V; Becker J; Soufir N; Hemminki K; Kumar R
Nat Commun; 2014 Feb; 5():3401. PubMed ID: 24569790
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
